Sensei Biotherapeutics Investor Relations Material

Sensei Biotherapeutics, Inc. is an immuno-oncology company dedicated to the discovery and development of next-generation therapeutics aimed at treating cancer patients. The company's innovative approach is centered on its TMAb™ (Tumor Microenvironment Activated biologics) platform, which develops conditionally active therapeutics. These therapeutics are designed to selectively disable checkpoints and other immunosuppressive signals in the tumor microenvironment, thereby unleashing T cells against tumors. Among its pipeline, the lead investigational candidate is SNS-101, a conditionally active antibody tailored to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint within the tumor's low pH environment, where VISTA suppresses T cell activity by binding the PSGL-1 receptor. The company is headquartered in Rockville, Maryland, with an additional office in Boston, Massachusetts, and its shares are listed on the Nasdaq.